| Literature DB >> 35954922 |
María-José Estebanez-Pérez1, José-Manuel Pastora-Bernal1, Rocío Martín-Valero1.
Abstract
Long COVID-19 has been defined as the condition occurring in individuals with a history of probable or confirmed SARS-CoV-2 infection, with related symptoms lasting at least 2 months and not explainable by an alternative diagnosis. The practice of digital physiotherapy presents itself as a promising complementary treatment method to standard physiotherapy, playing a key role in the recovery of function in subjects who have passed the disease and who maintain some symptomatology over time. The aims of this research are to explore the effect of a digital physiotherapy intervention on functional recovery in patients diagnosed with Long COVID-19 and to identify the level of adherence to the treatment carried out. A quasi-experimental pre-post study assessed initially and at the end of the 4-week intervention the functional capacity (1-min STS and SPPB) and the adherence (software) of a total of 32 participants. After the 4-week digital physiotherapy practice intervention with an individualised and customise exercise programme, a statistically significant improvement was observed (p < 0.05) with a small to medium effect size, high adherence rates and values above the minimal clinically important difference (MCID). We consider our intervention feasible, safe and consistent with our objectives. However, further randomised clinical trials and studies with larger samples are needed to draw extrapolable conclusions. Trial registration NCT04742946.Entities:
Keywords: Long COVID-19; digital physiotherapy practice; functional capacity; telerehabilitation; therapeutic adherence
Mesh:
Year: 2022 PMID: 35954922 PMCID: PMC9367987 DOI: 10.3390/ijerph19159566
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Flow diagram study design.
Figure 2Example of an individualised exercise programme.
Figure 3The Short Physical Performance Battery (SPPB) test. Reprinted with permission from Ref. [48]. Copyright 2021, copyright Riskowski, J.L. et al.
Participants characteristics.
| Participants ( | |
|---|---|
| Age (Mean/SD) | 45.93 ± 10.65 |
| Gender Woman % ( | 71.9% (23) |
| Non-Hospitalised % ( | 90.6% (29) |
| ICU % ( | 6.3% (2) |
Comorbidities distribution.
| Comorbidities Long COVID-19 | % | |
|---|---|---|
| Orthopaedic Pathology (Spine Surgery, Herniated Disc, Scoliosis, Hyper lordosis, Sacral Lumbarisation, Sacroiliitis, Shoulder Tendinopathy, Osteochondritis, Osteomalacia, Osteoarthritis and Osteoarthritis) | 15 | 46.88% |
| Respiratory Pathology (Asthma, Bronchial Hyperresponsiveness and Chronic Pharyngitis) | 11 | 34.38% |
| Endocrine Pathology (Thyroid Pathology and Diabetes) | 4 | 12.50% |
| Circulatory Pathology (Heart disease, Varicose veins and Hypertension) | 3 | 9.38% |
| Inflammatory Pathology (Sarcoidosis and Pancreatitis) | 2 | 6.25% |
| Depression | 2 | 6.25% |
| Immunological disorders (seasonal allergies) | 2 | 6.25% |
| Viral Deseases (Herpes Zoster and Mononucleosis) | 2 | 6.25% |
| Headaches | 2 | 6.25% |
| Myasthenia | 1 | 3.13% |
| Colic | 1 | 3.13% |
| Ureter Reflux | 1 | 3.13% |
Figure 4Presence of comorbidities.
Results of the 1-min STS: the 1-min STS test and SPPB: the short performance physical battery test.
| Initial (M/SD) | Final (M/SD) | Correlation | Sig. | Cohen’s d | Effect Size r | Effect Size | |
|---|---|---|---|---|---|---|---|
| 1-min STS | 14.03/7.84 | 17.53/7.44 | 0.81 | 0.00 | 0.45 | 0.22 | Small |
| SPPB | 7.90/1.98 | 9.12/1.69 | 0.72 | 0.00 | 0.66 | 0.31 | Medium |
| Balance test (SPPB) | 3.65/0.60 | 3.96/0.17 | 0.50 | 0.00 | 0.70 | 0.33 | Medium |
| Gait Speed test (SPPB) | 2.87/1.09 | 3.34/0.90 | 0.72 | 0.00 | 0.46 | 0.22 | Small |
| Chair Stand test (SPPB) | 1.37/0.90 | 1.81/1.09 | 0.66 | 0.00 | 0.43 | 0.21 | Small |
M: Media, SD: Standard deviation, Correlation: Correlation and Sig: Bilateral signification.